Kineta, Inc. KA
At closeSep 18, 2024, 4:00 PM EDT
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 7.05M
- EPS (ttm)
- -1.64
- Shares out
- 12.26M
- P/E ratio
- -0.35
- Forward P/E
- -0.43
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 480.68K
- Avg volume
- 504.10K
- Open
- 0.7801
- Previous close
- 0.5746
- Day's range
- 0.56 – 0.825
- 52-week range
- 0.3339 – 5.39
- Analysts
- Buy
- Price target
- 13.50 (+2249.5%)
- Earnings date
- Nov 1, 2024
Key statistics
- Enterprise value
- 8.55M
- PEG ratio
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -3.17M
- Total cash
- 900.00K
- Total debt
- 710.00K
- Return on equity
- 0.00%
- Short % of float
- 0.31%
- 50-day average
- 0.649607
- 200-day average
- 1.12
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 1, 2024
Expected Nov 1, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 1, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.29 | — | — | — |
| Nov 3, 2023 | Sep 1, 2023 | -0.55 | — | — | — |
| Aug 11, 2023 | Jun 1, 2023 | -0.62 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 17, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 30, 2023 | HC Wainwright & Co. | init | — | Buy |
About Kineta, Inc.
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kinetabio.com
News
TuHURA Biosciences Completes Acquisition of Kineta 
TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals 
TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting 
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANT 
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of TuHURA Biosciences, Inc. - HURA 
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc. 
Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024) 
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 
Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1 
Kineta, Inc Transitioning from Nasdaq to OTC Markets
Your note
Sign in to keep a note on KA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER KEITH | Chief Financial Officer | Purchase | Sep 17, 2023 | 16,880 |
| BARTOSZEK RAYMOND JOSEPH | Director | Purchase | Dec 5, 2023 | 863,685 |
| FOOTE MARION R | Director | Conversion of Exercise of derivative security | Oct 10, 2023 | 143,204 |
| GUILLAUDEUX THIERRY | Officer | Purchase | Sep 13, 2023 | 21,696 |
| IADONATO SHAWN P | Chief Executive Officer | Purchase | Nov 28, 2023 | 683,783 |
| KENNY PAULINE | General Counsel | Purchase | Sep 19, 2023 | 18,448 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.97% | 876,000 | 2.26M | Jun 29, 2023 |
| Colony Group LLC | 1.42% | 139,201 | 359.14K | Jun 29, 2023 |
| FMR, LLC | 1.27% | 123,719 | 319.19K | Jun 29, 2023 |
| Vanguard Group Inc | 0.63% | 61,561 | 158.83K | Jun 29, 2023 |
| Artal Group S.A. | 0.32% | 31,055 | 80.12K | Jun 29, 2023 |
| Renaissance Technologies, LLC | 0.28% | 26,916 | 69.44K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.34% | 32,976 | 85.08K | Jun 29, 2023 |
| Fidelity Growth Company Fund | 0.31% | 30,558 | 60.81K | Aug 30, 2023 |
| Vanguard Extended Market Index Fund | 0.29% | 28,255 | 72.90K | Jun 29, 2023 |
| iShares Micro Cap ETF | 0.13% | 12,978 | 25.83K | Aug 30, 2023 |
| Schwab Capital Trust-Total Stock Market Index Fund | 0.08% | 8,000 | 16.88K | Jul 30, 2023 |
| Fidelity Growth Company K6 Fund | 0.05% | 5,211 | 15.69K | May 30, 2023 |